| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
32.08(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$206.32 - $377.47 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
124,951 |
282,025 |
1,655,280 |
20,857,643 |
| Total Sell Value |
$39,701,704 |
$89,098,590 |
$441,317,064 |
$2,147,483,647 |
| Total People Sold |
4 |
6 |
9 |
11 |
| Total Sell Transactions |
10 |
19 |
60 |
95 |
| End Date |
2025-11-09 |
2025-08-08 |
2025-02-07 |
2024-02-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lee Chan Henry |
SVP, General Counsel |
• – – |
2026-02-04 |
4 |
AS |
$348.79 |
$580,197 |
D/D |
(1,660) |
0 |
|
- |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2026-02-04 |
4 |
OE |
$159.03 |
$317,721 |
D/D |
1,660 |
1,660 |
|
- |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2026-01-07 |
4 |
AS |
$331.76 |
$220,289 |
D/D |
(664) |
0 |
|
2% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2026-01-07 |
4 |
OE |
$159.03 |
$127,196 |
D/D |
664 |
664 |
|
- |
|
| Wang Lai |
President, Global Head of R&D |
• – – |
2025-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
427,895 |
1,451,424 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2025-12-16 |
4 |
AS |
$300.80 |
$7,380,739 |
D/D |
(24,369) |
0 |
|
12% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2025-12-15 |
4 |
AS |
$301.58 |
$23,278,679 |
D/D |
(75,631) |
24,369 |
|
10% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-12-11 |
4 |
AS |
$325.00 |
$107,900 |
D/D |
(332) |
0 |
|
6% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-12-11 |
4 |
OE |
$159.03 |
$63,598 |
D/D |
332 |
332 |
|
- |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-12-10 |
4 |
AS |
$318.28 |
$105,669 |
D/D |
(332) |
0 |
|
5% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-12-10 |
4 |
OE |
$159.03 |
$63,598 |
D/D |
332 |
332 |
|
- |
|
| Sanders Corazon (corsee) D. |
Director |
– • – |
2025-11-26 |
4 |
S |
$340.20 |
$895,534 |
D/D |
(2,627) |
0 |
|
-2% |
|
| Sanders Corazon (corsee) D. |
Director |
– • – |
2025-11-26 |
4 |
OE |
$159.03 |
$417,772 |
D/D |
2,627 |
2,627 |
|
- |
|
| Wu Xiaobin |
President and COO |
• – – |
2025-11-17 |
4 |
S |
$380.23 |
$1,518,303 |
D/D |
(3,991) |
0 |
|
8% |
|
| Wu Xiaobin |
President and COO |
• – – |
2025-11-13 |
4 |
S |
$380.33 |
$2,286,660 |
D/D |
(6,009) |
0 |
|
6% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-11-12 |
4 |
AS |
$348.75 |
$347,770 |
D/D |
(996) |
0 |
|
-10% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-11-12 |
4 |
OE |
$159.03 |
$190,704 |
D/D |
996 |
996 |
|
- |
|
| Wu Xiaobin |
President and COO |
• – – |
2025-11-12 |
4 |
S |
$350.44 |
$3,560,161 |
D/D |
(10,000) |
6,009 |
|
8% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2025-11-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
858,533 |
6,441,041 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2025-11-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
151,320 |
7,299,574 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2025-11-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
424,073 |
4,582,601 |
|
- |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-10-08 |
4 |
AS |
$347.82 |
$3,739,108 |
D/D |
(10,671) |
0 |
|
-3% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-10-08 |
4 |
OE |
$159.03 |
$2,017,363 |
D/D |
9,559 |
9,559 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2025-09-16 |
4 |
AS |
$324.12 |
$9,055,694 |
D/D |
(27,803) |
0 |
|
3% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-09-10 |
4 |
AS |
$325.00 |
$3,257,289 |
D/D |
(10,006) |
0 |
|
6% |
|
692 Records found
|
|
Page 1 of 28 |
|
|
6.92 (1.99%) 
